Limited Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin
Anges Yadouléton, Anna-Lena Sander, Andrés Moreira‐Soto, Carine Tchibozo, Gildas Hounkanrin, Yvette Badou, Carlo Fischer, Nina Krause, Petas Akogbeto, Edmilson Ferreira de Oliveira-Filho, Anges Dossou, Sebastian Brünink, Melchior Aïssi, Mamoudou Harouna Djingarey, Benjamin Hounkpatin, Michael Nagel, Jan Felix Drexler
Abstract
S ince its emergence in China late 2019, coronavirus disease (COVID-19) had caused >41 million cases and >1.1 million deaths globally by October 2020, according to the World Health Organization (https://www.who. int/publications/m/item/weekly-operational-update---30-october-2020). Diagnosis of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is based on reverse transcription-PCR (RT-PCR) to detect viral nucleic acid or serologic assays to detect SARS-CoV-2 antigens in early stages of disease (1,2). In later stages of disease, antibody-based serologic testing can complement diagnosis of SARS-CoV-2 |infection.